Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisEntecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient: A Case Report and Literature ReviewChronic Hepatitis B with Spontaneous Severe Acute ExacerbationThe Role of Oxidative Stress and Antioxidants in Liver DiseasesApplication of nucleoside analogues to liver transplant recipients with hepatitis BΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationManagement of patients with hepatitis B in special populationsCurrent and future antiviral drug therapies of hepatitis B chronic infectionOverview and recent trends of systematic reviews and meta-analyses in hepatology.AASLD guidelines for treatment of chronic hepatitis B.Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysisEntecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.Management of chronic hepatitis B in severe liver disease.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
P2860
Q26740323-C15B9415-1119-4264-A05A-83038236CED6Q26750766-1CE9AE7E-66ED-4CD6-9F9A-7C15E4A4D49AQ26772036-A9F4C31F-BF77-4088-88EF-F3CED7C2A708Q26779146-64039901-209C-4870-9D95-374D0FE6948EQ26859796-24005A82-E598-4ED9-A13F-D2F48B6BBA17Q26864647-EFBD8B2A-DF85-4DEE-86CF-728DD71FB87BQ27016136-3F091BAC-AD76-4328-93FA-6B3F3E5F7930Q28084820-A81B20BB-8819-4C95-84AA-47986A318545Q30434752-8499EEC6-BCA9-48FF-839C-8539DAC7E05AQ34501660-DBE9490F-7104-48E0-9212-A92E4F7F70E1Q35078035-49943939-B69E-4FAA-A8A1-BD6872E803E1Q36335540-F1CCAEB9-9359-4152-BFAD-C570B3643FAFQ37236357-79BFE747-4EC1-48D3-8748-04FB56335AA8Q38665203-BDBAD1DA-97D3-46C9-981A-B2F7935F35FEQ39018635-B51FF3F4-4562-4621-81C3-65D4CE7189FBQ40791821-977F347B-A69C-4198-A9D0-185A2F041DB4Q41619231-4541BF76-34D0-43B0-B21F-882D069C797FQ50190669-B16F1D1A-704B-4B16-90F4-4B0B96ABE270Q58602121-93CA2989-691B-452D-9765-B3AB0FFC1F44
P2860
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@en
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@nl
type
label
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@en
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@nl
prefLabel
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@en
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@nl
P2860
P356
P1476
Effects of entecavir and lamiv ...... ated cirrhosis: meta-analysis.
@en
P2093
Xiao-Guang Ye
P2860
P304
P356
10.3748/WJG.V19.I39.6665
P407
P577
2013-10-01T00:00:00Z